Fresenius SE & Co. KGaA

OTCPK:FSNU.F Stock Report

Market Cap: US$21.3b

Fresenius SE KGaA Valuation

Is FSNU.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FSNU.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$86.82
Fair Value
60.9% undervalued intrinsic discount
15
Number of Analysts

Below Fair Value: FSNU.F ($33.97) is trading below our estimate of fair value ($86.82)

Significantly Below Fair Value: FSNU.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FSNU.F?

Key metric: As FSNU.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for FSNU.F. This is calculated by dividing FSNU.F's market cap by their current revenue.
What is FSNU.F's PS Ratio?
PS Ratio0.9x
Sales€22.81b
Market Cap€20.49b

Price to Sales Ratio vs Peers

How does FSNU.F's PS Ratio compare to its peers?

The above table shows the PS ratio for FSNU.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2x
LH Labcorp Holdings
1.6x4.9%US$20.0b
DGX Quest Diagnostics
1.8x5.1%US$16.9b
DVA DaVita
1.1x3.5%US$13.6b
CHE Chemed
3.5x6.2%US$8.3b
FSNU.F Fresenius SE KGaA
0.9x3.6%US$20.5b

Price-To-Sales vs Peers: FSNU.F is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (2x).

Price to Sales Ratio vs Industry

How does FSNU.F's PS Ratio compare vs other companies in the US Healthcare Industry?

27 CompaniesPrice / SalesEstimated GrowthMarket Cap
MCK McKesson
0.2x8.5%US$75.22b
CVS CVS Health
0.2x4.5%US$66.22b
COR Cencora
0.2x6.5%US$46.78b
CNC Centene
0.2x5.5%US$31.43b
FSNU.F 0.9xIndustry Avg. 1.2xNo. of Companies27PS012345+
27 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: FSNU.F is good value based on its Price-To-Sales Ratio (0.9x) compared to the US Healthcare industry average (1.2x).

Price to Sales Ratio vs Fair Ratio

What is FSNU.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FSNU.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate FSNU.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst FSNU.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$33.97
US$42.50
+25.1%
11.6%US$54.59US$30.90n/a15
Jan ’26n/a
US$42.96
0%
11.5%US$55.72US$31.54n/a15
Dec ’25US$34.66
US$42.13
+21.6%
12.4%US$55.56US$31.45n/a15
Nov ’25n/a
US$42.83
0%
11.3%US$53.97US$32.38n/a15
Oct ’25US$37.35
US$43.77
+17.2%
11.1%US$55.54US$33.32n/a15
Sep ’25n/a
US$42.59
0%
12.9%US$55.11US$33.07n/a15
Aug ’25US$34.15
US$41.70
+22.1%
12.9%US$53.95US$32.37n/a15
Jul ’25n/a
US$39.93
0%
14.1%US$53.58US$30.01n/a16
Jun ’25n/a
US$39.88
0%
14.8%US$54.29US$30.41n/a16
May ’25n/a
US$38.85
0%
15.0%US$53.64US$30.04n/a16
Apr ’25n/a
US$39.14
0%
15.0%US$54.03US$30.26n/a16
Mar ’25US$27.98
US$41.29
+47.6%
25.0%US$75.66US$30.26n/a17
Feb ’25US$28.84
US$41.69
+44.6%
24.1%US$75.63US$32.41n/a17
Jan ’25n/a
US$41.88
0%
24.6%US$75.84US$32.50n/a16
Dec ’24US$31.00
US$42.27
+36.3%
25.1%US$76.90US$32.52US$34.6616
Nov ’24US$25.77
US$40.87
+58.6%
23.7%US$72.17US$31.42n/a16
Oct ’24n/a
US$41.28
0%
24.1%US$72.66US$31.63US$37.3516
Sep ’24US$32.00
US$41.44
+29.5%
24.6%US$74.15US$30.53n/a17
Aug ’24US$32.00
US$40.24
+25.7%
27.5%US$75.87US$29.69US$34.1517
Jul ’24US$26.50
US$39.83
+50.3%
28.6%US$75.48US$28.44n/a16
Jun ’24n/a
US$41.07
0%
41.2%US$98.99US$27.98n/a15
May ’24US$28.02
US$40.70
+45.3%
43.8%US$100.92US$24.13n/a15
Apr ’24US$27.19
US$38.47
+41.5%
46.1%US$98.80US$17.83n/a16
Mar ’24US$27.50
US$37.27
+35.5%
47.6%US$97.33US$17.56US$27.9816
Feb ’24n/a
US$38.62
0%
47.0%US$100.01US$18.05US$28.8416
Jan ’24US$26.94
US$37.23
+38.2%
48.1%US$97.69US$17.63n/a16
Analyst Price Target
Consensus Narrative from 15 Analysts
US$38.53
Fair Value
11.8% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 03:09
End of Day Share Price 2025/01/16 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fresenius SE & Co. KGaA is covered by 49 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martin SchneeAlphaValue
Hassan Al-WakeelBarclays
Robert BateBarclays